one
excit
develop
antivir
research
discoveri
directact
antivir
daa
effect
cure
chronic
hepat
c
viru
hcv
infect
base
clinic
trial
realworld
studi
provid
comprehens
overview
fdaapprov
therapi
newli
discov
antihcv
agent
special
focu
drug
efficaci
mechan
action
safeti
show
hcv
drug
develop
advanc
multipl
aspect
interferonbas
regimen
replac
interferonfre
regimen
ii
genotypespecif
drug
evolv
drug
hcv
genotyp
iii
therapi
base
upon
multipl
pill
per
day
simplifi
singl
pill
per
day
iv
drug
potenc
increas
moder
high
level
sustain
virolog
respons
v
treatment
durat
shorten
week
vi
therapi
could
administ
oral
regardless
prior
treatment
histori
cirrhot
statu
howev
despit
remark
achiev
made
hcv
drug
discoveri
challeng
remain
manag
difficulttotreat
patient
elbasvir
grazoprevir
past
two
decad
tremend
attempt
made
discov
antivir
drug
effect
treat
hepat
c
viru
hcv
infect
de
clercq
de
clercq
de
clercq
welzel
et
al
de
clercq
li
first
gener
fdaapprov
hcv
drug
includ
interferon
approv
year
discontinu
due
sever
advers
event
ribavirin
pegyl
interferon
pegyl
interferon
drug
low
cure
rate
may
caus
sever
advers
event
mann
et
al
yet
standardofcar
treatment
decad
still
popular
sever
countri
subsequ
directact
antivir
daa
repres
breakthrough
vitro
experi
clinic
trial
may
telaprevir
boceprevir
becam
first
fdaapprov
drug
daa
class
advent
daa
mark
new
era
antihcv
drug
directli
target
hcv
protein
offer
promis
cure
rate
minimum
advers
event
similar
cocktail
therapi
human
immunodefici
viru
combin
therapi
target
differ
stage
hcv
life
cycl
conceiv
avoid
crossresist
importantli
cure
rate
could
attain
clinic
trial
realworld
cohort
forthcom
therapi
endow
higher
cure
rate
shorter
treatment
durat
lesser
side
effect
base
upon
allor
regimen
review
aim
summar
latest
trend
hcv
drug
develop
focus
fdaapprov
therapi
newli
discov
agent
hcv
genotyp
infect
first
provid
gener
overview
hcv
infect
subsequ
summar
approv
hcv
drug
highlight
efficaci
clinic
trial
recent
develop
new
agent
describ
challeng
hcv
drug
develop
discuss
end
endors
review
movi
teach
slide
highlight
hcv
drug
action
avail
onlin
platform
http
www
virusfacecom
procedur
literatur
select
describ
search
literatur
pubm
use
keyword
hcv
drug
within
public
period
search
recent
public
unavail
pubm
similar
queri
also
perform
visit
websit
eleven
journal
nejm
jama
lancet
lancet
infecti
diseas
gut
clinic
infecti
diseas
gastroenterolog
hepatolog
journal
hepatolog
american
journal
gastroenterolog
annal
intern
medicin
clinic
trial
phase
stage
consid
case
report
exclud
literatur
review
small
sampl
rare
subject
also
extract
inform
clinic
trial
clinicaltrialsgov
http
wwwclinicaltrialsgov
european
clinic
trial
databas
eudract
http
eudractema
europaeuindexhtml
clinic
studi
drug
label
fda
http
wwwaccessdatafdagov
also
includ
literatur
search
three
exclus
criteria
undertaken
first
data
metaanalysi
report
summar
clinic
trial
public
consid
avoid
duplic
second
public
eg
hcvtarget
terrault
et
al
realworld
studi
backu
et
al
report
coinfect
hcv
infecti
diseas
eg
hiv
hbv
collect
coinfect
beyond
focu
review
third
order
highlight
svr
rate
antivir
drug
hcv
genotyp
public
clearli
address
svr
rate
hcv
therapi
individu
genotyp
summar
moreov
commun
everi
correspond
author
svr
rate
certain
patient
group
address
public
manag
obtain
svr
data
public
except
phase
studi
osinusi
et
al
anr
cupilt
studi
studi
sulkowski
et
al
cedg
studi
sperl
et
al
cedg
treatmentexperienc
studi
kwo
et
al
hepat
c
viru
hepaciviru
flavivirida
famili
first
discov
serum
person
nona
nonb
hepat
kuo
et
al
hcv
found
worldwid
popul
shepard
et
al
immedi
sourc
hcv
associ
pandem
spread
trace
circul
central
west
subsaharan
africa
south
southeast
asia
hundr
year
simmond
although
origin
remain
unclear
hcv
might
origin
zoonot
sourc
nonhuman
primat
eg
monkey
ape
mammal
eg
dog
hors
simmond
today
hcv
recogn
one
lethal
infecti
diseas
next
measl
influenza
respiratori
syncyti
viru
rotaviru
hepat
b
human
immunodefici
viru
mortal
diseas
et
al
accord
global
health
survey
million
peopl
current
live
hcv
caus
approxim
death
everi
year
importantli
hcvinfect
patient
unawar
statu
worldwid
popul
cox
singl
hcv
particl
approxim
nm
rang
nm
diamet
catanes
et
al
contain
linear
positivesens
singlestrand
rna
genom
encod
viral
protein
moradpour
penin
fig
due
sequenc
variat
differ
hcv
strain
genotyp
genotyp
recogn
global
preval
unequ
distribut
among
hcv
genotyp
genotyp
domin
global
infect
genotyp
circul
approxim
hcv
infect
genotyp
account
remain
less
messina
et
al
genotyp
identifi
far
patient
origin
central
africa
murphi
et
al
worth
mention
nucleotid
divers
hcv
genom
approxim
hcv
genotyp
within
hcv
genotyp
cuyper
et
al
averag
virion
produc
per
day
hcvinfect
patient
neumann
et
al
moreov
hcv
evolv
fast
hcv
mutat
rate
approxim
nucleotid
substitut
per
genom
site
per
year
ogata
et
al
bloodborn
viru
hcv
transmit
blood
transfus
needl
share
sexual
contact
matern
transmiss
although
hcv
circul
mani
human
organ
infect
predomin
hepatocyt
liver
evad
host
innat
adapt
immun
system
rehermann
incub
period
week
hcv
infect
begin
acut
phase
usual
goe
undiagnos
length
approxim
amino
acid
hcv
genom
code
three
structur
protein
core
seven
nonstructur
protein
whose
amino
acid
posit
map
accordingli
untransl
region
utr
untransl
region
utr
also
indic
approv
antivir
agent
directli
target
effect
inhibit
hcv
replic
b
total
compound
plu
ritonavir
display
circl
color
link
center
visual
drug
combin
notabl
x
approv
fda
could
use
without
ribavirin
xi
xii
approv
japan
xiii
current
assess
fda
two
discontinu
drug
boceprevir
telaprevir
indic
green
text
figur
show
hcv
combin
drug
compos
antihcv
inhibitor
differ
drug
class
symptomat
infect
asymptomat
infect
observ
maheshwari
et
al
approxim
symptomat
infect
asymptomat
infect
undertak
spontan
viral
clearanc
indic
hcv
clear
hcvinfect
patient
specif
immun
respons
maheshwari
et
al
clear
acut
hcv
evolv
chronic
hcv
without
proper
treatment
patient
chronic
hcv
threaten
seriou
complic
cirrhosi
liver
cancer
liver
failur
thrift
et
al
note
liver
damag
consequ
longlast
inflamm
host
immun
respons
activ
fight
hcv
infect
antonelli
et
al
accord
center
diseas
control
prevent
cdc
hcvrelat
cirrhosi
often
observ
patient
chronic
infect
period
year
advanc
cirrhosi
eventu
caus
endstag
liver
diseas
liver
failur
debilit
symptom
hepat
encephalopathi
portal
hypertens
hepatoren
syndrom
hepatocellular
carcinoma
ge
runyon
common
type
liver
cancer
hepatocellular
carcinoma
found
hcvinfect
patient
three
decad
elserag
nevertheless
success
antihcv
treatment
reduc
overal
mortal
risk
death
among
hcv
patient
compens
cirrhosi
nahon
et
al
hcv
genom
encod
structur
protein
core
nonstructur
protein
fig
similar
genomewid
protein
interact
human
immunodefici
viru
hcv
protein
cooper
play
multipl
function
take
part
differ
stage
viral
life
cycl
dubuisson
cosset
bartenschlag
et
al
major
function
hcv
protein
briefli
describ
herein
core
protein
key
element
form
viral
nucleocapsid
encapsul
hcv
rna
genom
insid
viral
particl
ii
envelop
glycoprotein
constitut
noncoval
complex
take
part
receptor
bind
fusion
process
viral
entri
iii
nonstructur
protein
form
hexam
cation
channel
activ
play
multipl
role
viral
particl
matur
releas
scull
et
al
iv
autoproteas
cleav
link
polyprotein
hcv
polyprotein
process
v
proteas
cofactor
structur
complex
cleav
four
link
polyprotein
releas
matur
vi
induc
format
membran
web
serv
principl
site
viral
replic
assembl
egger
et
al
gosert
et
al
vii
phosphoprotein
replicas
factor
interact
mani
viral
host
protein
regul
hcv
replic
bartenschlag
et
al
viii
polymeras
key
enzym
synthes
viral
rna
produc
new
viral
particl
overal
ten
hcv
protein
play
import
role
viral
life
cycl
make
potenti
drug
target
inhibit
hcv
replic
infect
detail
hcv
life
cycl
found
review
bartenschlag
et
al
moradpour
et
al
scheel
rice
lindenbach
rice
bartenschlag
et
al
discoveri
multifunct
aspect
hcv
protein
shed
light
novel
mechan
antihcv
drug
known
drug
target
includ
one
nonstructur
protein
two
hcv
enzym
de
clercq
three
drug
target
therefor
offer
ideal
drug
bind
pocket
design
hcv
combin
therapi
lead
tremend
success
pangenotyp
therapi
eg
epclusa
sustain
virolog
respons
approv
daa
combin
therapi
commonli
compos
two
three
compound
inhibit
either
differ
mechan
drug
action
fig
comparison
individu
compound
combin
therapi
offer
much
higher
efficaci
inhibit
hcv
infect
four
class
drug
action
discov
first
inhibitor
eg
asunaprevir
boceprevir
telaprevir
paritaprevir
grazoprevir
simeprevir
vaniprevir
voxilaprevir
inhibit
enzymat
activ
second
inhibitor
eg
daclatasvir
ledipasvir
ombitasvir
elbasvir
velpatasvir
might
inhibit
replic
complex
format
endoplasm
reticulum
sequest
lipid
droplet
inhibit
viru
format
incivek
mg
telaprevir
bid
plu
pegifnarbv
pegifnarbv
sovaldi
mg
sofosbuvir
qd
ribavirin
mg
sofosbuvir
qd
pegifnarbv
dec
olysio
mg
simeprevir
mg
sofosbuvir
qd
mg
simeprevir
qd
pegifnarbv
nov
harvoni
fixeddos
combin
tablet
mg
ledipasvir
mg
sofosbuvir
qd
without
ribavirin
week
oct
viekira
two
fixeddos
combin
tablet
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
qd
plu
mg
dasabuvir
bid
without
ribavirin
week
dec
two
fixeddos
combin
tablet
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
without
ribavirin
qd
week
juli
sovaldi
mg
daclatasvir
qd
mg
sofosbuvir
qd
without
ribavirin
week
juli
fixeddos
combin
tablet
mg
grazoprevir
qd
mg
elbasvir
qd
week
ribavirin
week
jan
epclusa
fixeddos
combin
tablet
mg
sofosbuvir
mg
velpatasvir
without
ribavirin
qd
week
june
victr
incivek
discontinu
except
hcv
therapi
could
appli
patient
cirrhosi
sunvepra
vanihep
approv
japan
list
tabl
releas
nettl
et
al
without
affect
stabil
dimer
inhibitor
block
hcv
rna
synthesi
stage
membran
web
biogenesi
berger
et
al
also
impair
viral
assembl
inhibit
deliveri
hcv
genom
assembl
site
boson
et
al
spite
high
potenc
inhibitor
slowli
inhibit
hcv
rna
synthesi
comparison
hcv
proteas
polymeras
inhibitor
mcgivern
et
al
also
worth
mention
cooper
interact
pair
inhibitor
may
enhanc
drug
resist
barrier
restor
antivir
activ
resist
variant
sun
et
al
third
nucleotid
inhibitor
eg
sofosbuvir
triphosph
bind
catalyt
site
compet
incom
nucleosid
triphosph
interrupt
rna
synthesi
fourth
nonnucleotid
inhibitor
eg
dasabuvir
bind
alloster
bind
pocket
outsid
catalyt
site
base
noncompetit
mechan
action
inhibit
rna
synthesi
gott
feld
addit
known
drug
bind
site
altern
drug
target
viral
host
protein
explor
experiment
drug
follow
section
provid
detail
approv
tertiari
structur
proteas
complex
simeprevir
pdb
code
shown
top
hcv
protein
display
orang
pink
respect
beneath
protein
chemic
structur
approv
experiment
inhibitor
tabl
demonstr
blue
arrow
indic
optim
initi
compound
fdaapprov
compound
boceprevir
njorog
et
al
telaprevir
kwong
et
al
simeprevir
rosenquist
et
al
grazoprevir
harper
et
al
liverton
et
al
red
structur
indic
differ
initi
compound
fdaapprov
compound
experiment
drug
interferon
infergen
first
fdaapprov
drug
hcv
infect
later
ribavirin
copegu
rebetol
virazol
pegyl
interferon
alfa
pegintron
intron
pegyl
interferon
alfa
pegasi
roferon
join
combat
hcv
infect
interferon
ribavirin
standard
care
therapi
wherea
offer
rather
low
clinic
effect
caus
seriou
side
effect
see
review
elsewher
advent
daa
open
era
potenti
cure
hcv
patient
de
clercq
de
clercq
de
clercq
januari
novemb
ten
therapi
approv
fda
tabl
well
two
approv
drug
asunaprevir
daclatasvir
vaniprevir
ribavirin
pegifna
japan
due
sever
side
effect
commerci
reason
telaprevir
boceprevir
discontinu
worth
mention
treatment
success
hcv
therapi
commonli
evalu
sustain
virolog
respons
svr
posttreat
week
week
instanc
svr
rate
may
vari
profoundli
hcv
therapi
use
differ
genotyp
patient
without
compens
cirrhosi
patient
experienc
without
previou
treatment
resist
aspect
hcv
daa
also
play
role
treatment
success
cuyper
et
al
sarrazin
therefor
american
european
guidelin
hepat
c
treatment
propos
differ
scenario
aasldidsa
hcv
guidanc
panel
european
associ
studi
liver
section
aim
summar
effect
fdaapprov
therapi
hcv
mono
infect
clinic
trial
realworld
studi
chemic
formula
approv
inhibitor
inhibitor
nucleosid
inhibitor
nonnucleosid
inhibitor
highlight
fig
respect
boceprevir
formerli
combin
pegifna
rbv
first
fdaapprov
therapi
hcv
genotyp
fig
tertiari
structur
hcv
structur
formula
approv
experiment
inhibitor
two
unit
dimer
color
pink
cyan
respect
inhibitor
daclatasvir
also
illustr
blue
arrow
indic
optim
initi
compound
fdaapprov
compound
ombitasvir
degoey
et
al
ledipasvir
link
et
al
daclatasvir
elbasvir
coburn
et
al
inhibitor
summar
tabl
infect
tabl
failur
screen
effort
four
million
compound
boceprevir
deriv
aketoamid
fig
use
structurebas
drug
design
approach
njorog
et
al
advanc
structurebas
drug
design
promot
discoveri
proteas
crystal
structur
reveal
kim
et
al
love
et
al
potent
proteas
inhibitor
boceprevir
block
serin
hydroxyl
hcv
proteas
njorog
et
al
accord
vitro
experi
ec
valu
boceprevir
nm
nm
nm
nm
nm
silva
et
al
may
fda
approv
clinic
use
boceprevir
plu
pegifnarbv
treatment
hcv
genotyp
infect
tabl
efficaci
approv
boceprevirbas
therapi
pegifnarbv
week
follow
mg
boceprevir
tid
plu
pegifnarbv
week
demonstr
phase
clinic
trial
summar
rate
therapi
genotyp
infect
regard
cirrhosi
prior
treatment
histori
tabl
patient
without
cirrhosi
rate
reach
hcvtarget
studi
sterl
et
al
phase
studi
studi
kwo
et
al
studi
treatmentexperienc
patient
without
cirrhosi
rate
hcvtarget
studi
sterl
et
al
phase
studi
studi
provid
studi
vierl
et
al
patient
cirrhosi
rate
approxim
phase
studi
sterl
et
al
poordad
et
al
poordad
et
al
kwo
et
al
treatmentexperienc
patient
cirrhosi
rate
clinic
trial
tabl
although
boceprevir
plu
pegifnarbv
first
fdaapprov
therapi
efficaci
supersed
new
daa
discontinu
announc
merck
may
fda
approv
clinic
use
mg
telaprevir
incivek
twice
daili
plu
pegifnarbv
week
follow
pegifnarbv
telaprevir
formerli
combin
pegifnarbv
second
fdaapprov
therapi
hcv
genotyp
infect
tabl
illustr
fig
telaprevir
discov
viral
substrat
sequenc
edvvccsmsi
hcv
proteas
use
structurebas
drug
design
approach
kwong
et
al
principl
base
fact
hcv
proteas
could
inhibit
cleavag
product
kwong
et
al
mechan
similar
proteas
inhibitor
explor
hiv
telaprevir
revers
noncoval
inhibitor
favor
pharmacokinet
profil
hcv
cell
cultur
anim
model
moreov
ec
valu
telaprevir
reach
nm
nm
hcv
replicon
assay
silva
et
al
effect
telaprevir
plu
pegifnarbv
hcv
demonstr
phase
clinic
trial
tabl
rate
therapi
patient
without
cirrhosi
tabl
group
treatmentexperienc
patient
without
cirrhosi
rate
fell
approxim
patient
cirrhosi
rate
hcvtarget
sterl
et
al
optim
studi
respect
treatmentexperienc
patient
cirrhosi
rate
attain
reddi
et
al
anr
studi
respect
although
telaprevir
show
favor
efficaci
clinic
trial
telaprevirbas
therapi
may
caus
fatal
nonfat
seriou
skin
reaction
stevensjohnson
syndrom
sj
drug
reaction
eosinophilia
system
symptom
dress
toxic
epiderm
necrolysi
ten
due
advent
nextgener
daa
vertex
pharmaceut
announc
discontinu
fig
tertiari
structur
hcv
structur
formula
approv
experiment
nucleosid
inhibitor
structur
complex
beclabuvir
sofosbuvir
diphosph
pdb
code
visual
top
discoveri
sofosbuvir
undertak
optim
path
f
cmethylcytidin
f
cmethyluridin
sofia
et
al
structur
formula
also
demonstr
telaprevir
decemb
fda
approv
clinic
use
sovaldi
hcv
genotyp
infect
mg
sofosbuvir
qd
plu
pegifnarbv
week
genotyp
ii
mg
sofosbuvir
qd
plu
ribavirin
week
genotyp
iii
mg
sofosbuvir
qd
plu
ribavirin
genotyp
sofosbuvir
formerli
discov
pharmasset
acquir
gilead
scienc
first
fdaapprov
nucleotid
analogu
inhibit
hcv
lawitz
et
al
select
inhibitor
hcv
polymeras
fig
nucleosid
select
optim
phosphoramid
prodrug
led
discoveri
sofosbuvir
sofia
et
al
fig
moreov
sofosbuvir
demonstr
potent
pangenotyp
activ
ec
valu
nm
nm
hcv
replicon
lam
et
al
favor
antivir
activ
sofosbuvir
also
found
primari
hepatocyt
rat
dog
monkey
sofia
et
al
importantli
sovaldi
first
fdaapprov
hcv
drug
oral
administ
oncedaili
lead
better
adher
excel
toler
safeti
efficaci
sofosbuvir
plu
pegifnarbv
demonstr
number
phase
clinic
trial
tabl
efficaci
mg
sofosbuvir
qd
plu
pegifnarbv
period
week
demonstr
clinic
studi
boson
foster
et
al
hcvtarget
feld
et
al
electron
gane
et
al
atom
neutrino
lawitz
et
al
kuld
ogawa
et
al
lawitz
et
al
merg
treatment
outcom
data
estim
drug
efficaci
regardless
distinct
natur
differ
clinic
trial
rate
therapi
approxim
tabl
particular
use
therapi
genotyp
approv
fda
tabl
illustr
efficaci
mg
sofosbuvir
qd
plu
ribavirin
week
clinic
studi
positron
fusion
electron
gane
et
al
fission
lawitz
et
al
hcvtarget
feld
et
al
welzel
et
al
rate
approxim
tabl
illustr
efficaci
mg
sofosbuvir
qd
plu
ribavirin
week
clinic
studi
foster
et
al
foster
et
al
valenc
zeuzem
et
al
boson
foster
et
al
rate
approxim
moreov
recurr
hcv
infect
liver
transplant
patient
includ
fibros
cholestat
hepat
decompens
cirrhosi
might
treat
sofosbuvir
plu
ribavirin
achiev
modest
efficaci
forn
et
al
common
side
effect
sofosbuvir
plu
pegifnarbv
fatigu
headach
nausea
insomnia
anemia
novemb
fda
approv
use
mg
simeprevir
qd
plu
pegifnarbv
genotyp
infect
ii
mg
simeprevir
plu
mg
sofosbuvir
qd
genotyp
infect
tabl
simeprevir
formerli
potent
inhibitor
target
hcv
rosenquist
et
al
fig
worth
mention
inhibitor
simeprevir
combin
inhibitor
sofosbuvir
consid
effici
inhibit
differ
stage
hcv
life
cycl
e
principl
line
standard
cocktail
treatment
hiv
simeprevir
discov
extens
explor
novel
cyclopentan
macrocycl
inhibitor
use
hcv
proteas
assay
cellular
replicon
system
structurebas
design
rosenquist
et
al
moreov
ec
valu
simeprevir
nm
nm
replicon
cell
genotyp
strain
genotyp
respect
lin
et
al
inde
simeprevir
show
excel
vitro
vivo
biolog
antivir
safeti
pharmacolog
profil
pave
way
clinic
trial
summar
efficaci
simeprevir
plu
sofosbuvir
pegifnarbv
phase
clinic
studi
cosmo
lawitz
et
al
lawitz
et
al
target
elkhayat
et
al
sulkowski
et
al
anr
hepath
attempt
estim
drug
efficaci
merg
clinic
data
regardless
distinct
natur
differ
clinic
trial
treatment
mg
simeprevir
plu
mg
sofosbuvir
qd
tabl
antivir
activ
fdaapprov
compound
hcv
cell
cultur
vitro
activ
ec
nm
ref
tabl
restor
studi
patient
receiv
simeprevir
plu
pegifnarbv
follow
pegifnarbv
rate
patient
without
cirrhosi
patient
cirrhosi
furthermor
simeprevir
plu
pegifnarbv
follow
addit
pegifnarbv
approv
patient
coinfect
hiv
hcv
infect
clinic
studi
common
side
effect
simeprevir
plu
sofosbuvir
fatigu
headach
nausea
simeprevir
plu
sofosbuvir
may
caus
common
advers
event
rash
pruritu
nausea
photosensit
reaction
octob
fda
approv
fixeddos
combin
tablet
mg
ledipasvir
mg
sofosbuvir
harvoni
without
ribavirin
treatment
hcv
genotyp
infect
ledipasvir
potent
inhibitor
fig
nucleotid
analogu
sofosbuvir
target
inhibit
activ
fig
ledipasvir
formerli
discov
seri
modif
unsymmetr
benzimidazoledifluorofluoreneimidazol
core
distal
azabicycl
ring
system
link
et
al
hcv
replicon
assay
ec
valu
ledipasvir
nm
nm
nm
nm
nm
nm
nm
nm
pharmacokinet
studi
anim
model
eg
rat
dog
monkey
support
potent
antivir
activ
ledipasvir
link
et
al
tabl
instanc
studi
indic
ledipasvir
sofosbuvir
ribavirin
therapi
week
led
high
rate
even
patient
decompens
cirrhot
liver
transplant
charlton
et
al
mann
et
al
attempt
estim
drug
efficaci
merg
clinic
data
regardless
distinct
natur
differ
clinic
trial
regard
treatment
tabl
moreov
drug
resist
mutat
baselin
exert
minim
effect
patient
respons
therapi
ledipasvir
plu
sofosbuvir
common
advers
event
treatment
harvoni
headach
fatigu
asthenia
ad
ribavirin
ledipasvir
plu
sofosbuvir
might
provid
addit
efficaci
certain
patient
popul
ad
valu
may
compens
increas
rate
treatmentassoci
advers
event
instanc
black
patient
wilder
et
al
ledipasvir
plu
sofosbuvir
safe
effect
infect
patient
compens
cirrhosi
use
treatmentexperienc
patient
compens
cirrhosi
requir
extend
treatment
durat
week
reddi
et
al
decemb
fda
approv
fixeddos
combin
tablet
paritaprevir
ombitasvir
ritonavir
copackag
dasabuvir
viekira
regard
mechan
drug
action
paritaprevir
formerli
ombitasvir
dasabuvir
antivir
inhibitor
hcv
protein
respect
addit
known
function
booster
hiv
proteas
inhibitor
ritonavir
viekira
effect
inhibit
human
gene
encod
import
enzym
human
bodi
oxid
small
foreign
organ
molecul
drug
metabol
inhibit
metabol
paritaprevir
thu
increas
plasma
concentr
paritaprevir
replicon
cell
line
paritaprevir
demonstr
potent
activ
differ
genotyp
ec
valu
paritaprevir
estim
nm
nm
nm
nm
nm
nm
base
cellcultur
experi
shown
ec
valu
ombitasvir
approxim
pm
pm
pm
pm
pm
pm
pm
pm
degoey
et
al
regard
discoveri
ombitasvir
optim
symmetr
seri
nphenylpyrrolidinebas
inhibitor
chiral
pyrrolidinebas
core
degoey
et
al
fig
dasabuvir
fig
nonnucleosid
inhibitor
target
alloster
site
within
palm
region
liu
et
al
ec
valu
dasabuvir
nm
nm
replicon
cell
line
kati
et
al
first
coformul
tripledaa
therapi
viekira
offer
signific
improv
genotyp
summar
efficaci
viekira
phase
clinic
studi
includ
pearlii
pearliii
pearliv
sapphirei
feld
et
al
rubyi
aviat
kowdley
et
al
malachitei
dore
et
al
malachiteii
dore
et
al
turquoiseii
turquoiseiii
feld
et
al
sapphireii
zeuzem
et
al
tabl
highlight
efficaci
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
oncedaili
fixeddos
two
pill
plu
mg
dasabuvir
bid
attempt
estim
drug
efficaci
merg
clinic
data
regardless
distinct
natur
differ
clinic
trial
rate
regimen
reach
patient
without
cirrhosi
patient
cirrhosi
patient
cirrhosi
ii
tabl
show
efficaci
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
oncedaili
fixeddos
two
pill
plu
mg
dasabuvir
bid
plu
ribavirin
base
clinic
studi
rate
therapi
reach
patient
without
cirrhosi
patient
cirrhosi
iii
tabl
illustr
efficaci
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
fixeddos
two
pill
qd
plu
mg
dasabuvir
bid
plu
ribavirin
turquoiseii
studi
rate
reach
patient
cirrhosi
overal
rate
viekira
achiev
treatment
patient
without
cirrhosi
common
side
effect
viekira
clinic
studi
fatigu
nausea
skin
rash
pruritu
insomnia
asthenia
juli
fda
approv
fixeddos
combin
ombitasvir
plu
paritaprevir
plu
ritonavir
without
ribavirin
patient
without
cirrhosi
first
fdaapprov
therapi
sole
infect
basic
lack
dasabuvir
comparison
viekira
product
manufactur
abbvi
sever
clinic
studi
pearli
studi
lawitz
et
al
hezod
et
al
gifti
studi
kumada
et
al
design
illustr
efficaci
tabl
fixeddos
combin
mg
ombitasvir
mg
paritaprevir
mg
ritonavir
taken
two
tablet
daili
week
rate
patient
without
cirrhosi
patient
cirrhosi
patient
without
cirrhosi
pearli
studi
rate
plu
ribavirin
achiev
patient
without
cirrhosi
common
advers
event
asthenia
nausea
fatigu
insomnia
juli
fda
approv
clinic
use
mg
daclatasvir
qd
plu
mg
sofosbuvir
qd
without
ribavirin
week
hcv
genotyp
infect
noteworthi
daclatasvir
sofosbuvir
bind
protein
respect
daclatasvir
design
extens
optim
lead
iminothiazolidinon
fig
obtain
high
throughput
phenotyp
screen
daclatasvir
symmetr
dimer
form
may
bind
posit
hcv
thu
interf
proteinprotein
interact
membran
interfac
nettl
et
al
moreov
cooper
interact
daclatasvir
inhibitor
eg
suggest
possibl
synergist
antihcv
activ
provid
addit
option
hcv
combin
therapi
sun
et
al
hcv
replicon
ec
valu
daclatasvir
achiev
nm
nm
nm
nm
nm
nm
tabl
moreov
pharmacokinet
analys
anim
model
eg
rat
dog
cynomolgu
monkey
support
potent
antivir
activ
daclatasvir
addit
combin
daclatasvir
plu
sofosbuvir
daclatasvir
previous
consid
use
asunaprevir
muir
et
al
toyota
et
al
although
combin
daclatasvir
plu
asunaprevir
declin
fda
regimen
approv
japan
efficaci
daclatasvir
plu
sofosbuvir
prove
sever
clinic
studi
tabl
tabl
realworld
studi
enrol
patient
rate
daclatasvir
plu
sofosbuvir
achiev
regardless
hcv
genotyp
cirrhosi
liver
transplant
hivhcv
coinfect
statu
welzel
et
al
common
advers
event
clinic
studi
headach
fatigu
januari
fda
approv
fixeddos
combin
mg
grazoprevir
plu
mg
elbasvir
without
ribavirin
hcv
genotyp
infect
tabl
grazoprevir
elbasvir
bind
hcv
respect
one
hand
grazoprevir
fig
discov
use
molecular
modelingderiv
strategi
optim
contact
proteas
inhibitor
macrocycl
ring
hcv
activ
site
harper
et
al
liverton
et
al
hand
elbasvir
discov
introduc
tetracycl
indol
earli
clinic
candid
fig
significantli
improv
virolog
profil
coburn
et
al
hcv
cellbas
replicon
ec
valu
grazoprevir
nm
nm
nm
nm
nm
nm
nm
lahser
et
al
meanwhil
ec
valu
elbasvir
achiev
nm
nm
nm
nm
nm
nm
nm
lahser
et
al
combin
grazoprevir
plu
elbasvir
exhibit
potent
activ
hcv
replic
harbor
higher
genet
barrier
drug
resist
compar
individu
compound
lahser
et
al
overal
grazoprevir
elbasvir
attain
potent
antivir
activ
cell
cultur
assay
anim
model
lahser
et
al
harper
et
al
coburn
et
al
efficaci
grazoprevir
plu
elbasvir
proven
mani
clinic
trial
cedg
lawitz
et
al
csalvag
forn
et
al
attempt
estim
drug
efficaci
merg
clinic
data
regardless
distinct
natur
differ
clinic
trial
tabl
regard
therapi
mg
grazoprevir
qd
mg
elbasvir
qd
rate
patient
without
cirrhosi
patient
cirrhosi
patient
without
cirrhosi
patient
without
cirrhosi
tabl
ii
regard
treatment
mg
grazoprevir
qd
mg
elbasvir
qd
rbv
bid
rate
fulfil
patient
without
cirrhosi
patient
cirrhosi
limit
number
enrol
patient
describ
cscape
studi
rate
noncirrhot
patient
infect
respect
due
enrol
patient
coinfect
hcv
hiv
cedg
te
studi
kwo
et
al
unabl
obtain
data
grazoprevir
elbasvir
rbv
treat
hcv
monoinfect
common
side
effect
anemia
headach
furthermor
polymorph
amino
acid
posit
may
reduc
treatment
efficaci
clinic
trial
komatsu
et
al
overal
combin
grazoprevir
plu
elbasvir
without
ribavirin
effect
safe
patient
infect
see
tabl
combin
mg
grazoprevir
mg
elbasvir
mg
sofosbuvir
recent
evalu
phase
cswift
studi
lawitz
et
al
therapi
tripledrug
combin
week
patient
infect
infect
demonstr
high
rate
lawitz
et
al
find
suggest
inhibitor
plu
inhibitor
inhibitor
may
offer
better
rate
shortdur
therapi
june
fda
approv
epclusa
first
fixeddos
combin
mg
sofosbuvir
plu
mg
velpatasvir
without
ribavirin
hcv
genotyp
infect
epclusa
first
pangenotyp
therapi
approv
treatment
hcv
genotyp
except
genotyp
global
preval
genotyp
rather
low
murphi
et
al
case
report
show
treatment
success
epclusa
one
patient
infect
hcv
genotyp
schreiber
et
al
key
compon
epclusa
velpatasvir
fig
discov
secondgener
inhibitor
potent
antivir
activ
cell
cultur
assay
ec
valu
velpatasvir
nm
nm
nm
nm
nm
nm
nm
nm
cheng
et
al
moreov
sofosbuvir
bestinclass
inhibitor
manufactur
gilead
scienc
thu
fast
approv
sofosbuvir
plu
velpatasvir
mark
new
era
antihcv
therapi
effect
cure
major
hcvinfect
patient
regardless
hcv
genotyp
unlik
fdaapprov
therapi
requir
treatment
epclusa
also
attain
promis
efficaci
week
effect
sofosbuvir
plu
velpatasvir
demonstr
phase
clinic
studi
feld
et
al
foster
et
al
foster
et
al
curri
et
al
see
summari
tabl
attempt
collect
treatment
outcom
estim
drug
efficaci
integr
data
regardless
distinct
natur
differ
clinic
trial
fixeddos
combin
mg
sofosbuvir
mg
velpatasvir
daili
rate
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
tabl
ii
fixeddos
combin
mg
sofosbuvir
mg
velpatasvir
daili
plu
ribavirin
score
patient
without
cirrhosi
versu
cirrhosi
patient
without
cirrhosi
versu
cirrhosi
tabl
common
advers
event
observ
clinic
studi
nausea
headach
fatigu
insomnia
anemia
diarrhea
past
three
year
advanc
hcv
drug
discoveri
made
produc
larg
amount
new
inhibitor
better
potenc
safeti
profil
previou
review
describ
experiment
compound
hcv
infect
de
clercq
de
clercq
de
clercq
de
clercq
li
section
updat
recent
progress
antihcv
agent
target
fig
fig
fig
fig
protein
fig
immunostimul
host
target
agent
inhibit
host
protein
also
summar
see
tabl
fig
develop
inhibitor
character
recent
review
de
clercq
de
clercq
li
mccauley
rudd
highlight
latest
advanc
danoprevir
voxilaprevir
vedroprevir
faldaprevir
discontinu
inhibitor
sheng
et
al
faldaprevir
narlaprevir
voxilaprevir
voxilaprevir
see
fig
inhibitor
enter
advanc
stage
clinic
trial
therapi
mg
voxilaprevir
combin
mg
velpatasvir
plu
mg
sofosbuvir
daili
examin
phase
clinic
trial
previou
phase
clinic
trial
investig
tripledaa
therapi
week
rate
patient
without
cirrhosi
patient
cirrhosi
lawitz
et
al
addit
treatment
attain
rate
daaexperienc
patient
without
cirrhosi
lawitz
et
al
anoth
phase
studi
show
high
efficaci
patient
infect
genotyp
demonstr
rate
treatmentexperienc
patient
without
cirrhosi
versu
treatmentexperienc
patient
cirrhosi
gane
et
al
third
clinic
trial
investig
treatment
combin
therapi
genotyp
infect
demonstr
treatment
provid
high
rate
experienc
patient
without
compens
cirrhosi
gane
et
al
clinic
trial
voxilaprevir
sofosbuvir
plu
velpatasvir
welltoler
caus
mild
moder
advers
event
lawitz
et
al
gane
et
al
gane
et
al
rodrigueztorr
et
al
octob
gilead
scienc
announc
latest
find
four
phase
trial
rate
oncedaili
singl
tablet
contain
voxilaprevir
sofosbuvir
velpatasvir
treatmentfailur
patient
infect
http
wwwgileadcom
decemb
gilead
scienc
submit
new
drug
applic
sofosbuvir
velpatasvir
plu
voxilaprevir
overal
combin
therapi
offer
shortdur
treatment
potenti
provid
salvag
therapi
daaexperienc
patient
vedroprevir
vedroprevir
revers
noncoval
inhibitor
effect
bind
activ
site
hcv
proteas
sheng
et
al
ec
valu
vedroprevir
determin
nm
nm
replicon
cell
line
respect
moreov
pharmacokinet
properti
vedroprevir
shown
rat
dog
monkey
sheng
et
al
phase
clinic
trial
combin
vedroprevir
ledipasvir
tegobuvir
plu
ribavirin
led
rate
patient
without
cirrhosi
phase
studi
combin
vedroprevir
plu
ledipasvir
sofosbuvir
week
reach
rate
patient
cirrhosi
lawitz
et
al
anoth
phase
trial
patient
without
cirrhosi
maintain
treatment
vedroprevir
plu
ledipasvir
sofosbuvir
week
kohli
et
al
octob
phase
trial
vedroprevir
establish
drug
pipelin
gilead
scienc
wwwgileadcom
tertiari
structur
experiment
inhibitor
six
unit
hexamer
channel
color
accordingli
pdb
code
drug
bind
site
locat
center
hcv
channel
ouyang
et
al
danoprevir
danoprevir
discov
base
joint
effort
structurebas
design
investig
structureact
relationship
optim
drug
metabol
pharmacokinet
jiang
et
al
macrocycl
noncoval
revers
inhibitor
slowoff
rate
exhibit
favor
potenc
across
multipl
hcv
genotyp
jiang
et
al
ic
valu
danoprevir
fig
nm
nm
nm
infect
jiang
et
al
moreov
danoprevir
may
restor
insulin
sensit
patient
moucari
et
al
earli
clinic
studi
support
clinic
use
danoprevir
plu
pegifnarbv
offer
modest
potenc
safeti
infect
gane
et
al
gane
et
al
foresti
et
al
marcellin
et
al
trial
danoprevir
plu
mericitabin
significantli
reduc
hcv
rna
level
patient
gane
et
al
matterhorn
studi
combin
danoprevirr
mericitabin
plu
pegifnarbv
week
welltoler
yield
rate
infect
feld
et
al
phase
trial
enrol
patient
without
cirrhosi
fourweek
treatment
danoprevir
ledipasvir
plu
sofosbuvir
exhibit
rate
kohli
et
al
accord
inform
clinicaltrialsgov
phase
trial
danoprevir
found
glecaprevir
glecaprevir
pibrentasvir
abbvi
inhibit
activ
hcv
fig
fig
respect
efficaci
safeti
mg
plu
mg
cirrhot
patient
infect
demonstr
phase
clinic
trial
gane
et
al
poordad
et
al
rate
succeed
plu
patient
patient
gane
et
al
meanwhil
rate
plu
ribavirin
reach
among
patient
gane
et
al
phase
magellani
studi
rate
mg
plu
mg
reach
patient
without
cirrhosi
poordad
et
al
phase
trial
ongo
faldaprevirdeleobuvir
faldaprevir
bi
deleobuvir
bi
two
experiment
inhibitor
target
fig
fig
respect
phase
studi
faldaprevir
nonnucleosid
inhibitor
deleobuvir
plu
ribavirin
offer
rate
rang
patient
although
degre
liver
fibrosi
may
affect
efficaci
faldaprevir
plu
deleobuvir
ribavirin
zeuzem
et
al
rate
therapi
rather
lower
daa
variat
amino
acid
posit
may
reduc
treatment
respons
berger
et
al
pursuit
faldaprevir
plu
deleobuvir
discontinu
narlaprevir
narlaprevir
sch
see
fig
secondgener
proteas
inhibitor
deriv
boceprevir
arasappan
et
al
comparison
boceprevir
narlaprevir
show
better
potenc
pharmacokinet
profil
physicochem
characterist
arasappan
et
al
earli
clinic
studi
suggest
narlaprevir
plu
pegifnarbv
offer
rate
patient
de
bruijn
et
al
singl
dose
mg
narlaprevir
exposur
higher
cirrhot
patient
healthi
patient
isakov
et
al
phase
trial
narlaprevir
clinicaltri
gov
identifi
termin
due
postmarket
commit
develop
narlaprevir
discontinu
fig
discov
acylsulfonamidebas
tripeptid
inhibit
hcv
proteas
scola
et
al
although
potenti
cardiovascular
liabil
clinic
trial
immedi
prompt
discontinu
small
modif
isoquinolon
ring
led
discoveri
asunaprevir
e
compound
free
cardiovascular
liabil
scola
et
al
remain
preclin
stage
fig
novel
spiroprolin
macrocycl
followup
compound
neelamkavil
et
al
base
ration
comput
model
structureguid
design
found
offer
robust
pangenotyp
activ
good
coverag
resist
strain
neelamkavil
et
al
optim
approv
inhibitor
asunaprevir
led
potent
acycl
tripeptid
acyl
sulfonamid
inhibitor
call
fig
enhanc
potenc
gentil
et
al
safeti
metabol
stabil
pharmacokinet
profil
remain
preclin
stage
today
inhibitor
approv
fda
recent
review
highlight
achiev
made
discoveri
inhibitor
although
inhibitor
remain
preliminari
stage
cannalir
et
al
inhibitor
fig
discov
optim
compound
exhibit
potent
activ
infect
offer
favor
pharmacokinet
profil
rat
dog
monkey
clinic
use
requir
investig
deriv
novel
inhibitor
harbor
scaffold
show
promis
inhibitori
activ
vitro
ec
valu
compound
nm
nm
nm
nm
nm
nm
phillip
et
al
clinic
use
requir
investig
imidazo
thiazol
deriv
experiment
inhibitor
imidazo
thiazol
scaffold
yield
synergist
respons
simeprevir
daclatasvir
sofosbuvir
lower
drug
dose
inhibit
hcv
infect
clinic
use
new
compound
requir
tertiari
structur
host
protein
cyclophilin
complex
phenylepyrrolidin
visual
pdb
code
addit
cyclophilin
inhibitor
includ
alisporivir
bisamid
deriv
tabl
compound
target
host
protein
offer
antivir
activ
see
detail
section
piperazinon
highthroughput
drug
screen
identifi
piperazinon
deriv
effect
inhibit
infect
direct
bind
hcv
nevertheless
piperazinon
class
insuffici
inhibit
infect
thu
develop
discontinu
number
experiment
inhibitor
current
develop
tabl
although
remain
preclin
candid
sever
compound
eg
samatasvir
ravidasvir
success
advanc
clinic
trial
section
provid
overview
new
inhibitor
includ
ruzasvir
ravidasvir
samatasvir
biphenylimidazol
analogu
disulfiram
fig
pibrentasvir
pibrentasvir
test
phase
trial
enrol
patient
without
cirrhosi
poordad
et
al
treatment
paritaprevir
ritonavir
plu
ribavirin
cure
patient
without
sever
advers
event
moreov
combin
show
high
efficaci
safeti
profil
phase
clinic
trial
see
section
develop
therefor
expect
ruzasvir
ruzasvir
potent
nextgener
inhibitor
discov
iter
lead
optim
compound
stepwis
screen
select
panel
hcv
replicon
cell
compound
maintain
ec
pm
across
hcv
uridin
nucleotid
analogu
target
hcv
ccrest
phase
clinic
studi
two
tripledrug
combin
grazoprevir
elbasvir
grazoprevir
examin
noncirrhot
patient
infect
infect
gane
et
al
shown
regimen
mg
mg
grazoprevir
plu
mg
effect
gain
infect
gane
et
al
phase
clinic
trial
ongo
samatasvir
potent
inhibitor
samatasvir
select
inhibit
hcv
replic
bilello
et
al
ec
valu
accomplish
pm
pm
pm
pm
pm
pm
bilello
et
al
proofofconcept
studi
samatasvirbas
monotherapi
welltoler
reduc
hcv
rna
level
substanti
patient
patient
infect
infect
vinc
et
al
absenc
merck
janssen
pipelin
samatasvir
appear
discontinu
ravidasvir
inhibitor
ravidasvir
dimer
benzimidazoleenaphthylene
imidazol
deriv
ec
valu
compound
nm
nm
nm
hcv
infect
respect
zhong
et
al
efficaci
safeti
profil
ravidasvir
combin
inhibitor
eg
faldaprevir
sofosbuvir
demonstr
preliminari
clinic
trial
zhong
et
al
phase
trial
ravidasvir
ongo
clinicaltri
gov
identifi
basi
ketalbas
improv
potenc
mutant
spiroket
pyrrolidin
harbor
nonan
motif
design
effect
inhibit
mutant
bear
comparison
daclatasvir
significantli
reduc
hcv
rna
level
studi
phase
studi
plu
pegifnarbv
exhibit
rapid
signific
antivir
activ
patient
wilfret
et
al
furthermor
mutat
ntermin
region
caus
decreas
activ
ongo
trial
current
unavail
databas
clinicaltri
gov
potent
select
compound
inhibit
activ
interfer
hcv
replic
owen
et
al
resist
profil
random
clinic
studi
reveal
drug
resist
mutat
owen
et
al
ongo
trial
current
unavail
databas
clinicaltri
gov
biarylimidazol
novel
biarylimidazol
chemotyp
potent
inhibitori
activ
toward
discov
order
remov
embed
anilin
moieti
earli
drug
candid
caus
genotox
variou
shortterm
test
activ
inhibitor
contain
linker
offer
potent
antivir
activ
ec
pm
favor
pharmacokinet
featur
rat
dog
ivachtchenko
et
al
disulfiram
old
antialcohol
drug
discov
disulfiram
recent
identifi
novel
znejector
eject
zn
labil
znsite
thu
lead
inhibit
hcv
infect
inspir
two
fdaapprov
inhibitor
sofosbuvir
dasabuvir
mani
experiment
compound
current
evalu
sever
candid
reach
advanc
clinic
trial
section
highlight
recent
progress
newli
discov
inhibitor
see
tabl
fig
beclabuvir
introduct
cyclopropyl
moieti
indolobenzazepin
inhibitor
led
discoveri
nonnucleosid
beclabuvir
favor
antivir
safeti
pharmacokinet
properti
gentl
et
al
clinic
trial
carri
examin
combin
beclabuvir
daclatasvir
plu
asunaprevir
without
ribavirin
muir
et
al
toyota
et
al
everson
et
al
everson
et
al
hassanein
et
al
rate
mg
beclabuvir
mg
daclatasvir
plu
mg
asunaprevir
exploratori
studi
phase
studi
anoth
phase
studi
studi
studi
phase
studi
overal
tripledaa
regimen
beclabuvir
plu
daclatasvir
asunaprevir
exert
promis
activ
infect
nonnucleosid
analogu
nalkyl
substitu
nacyl
group
discov
optim
lomibuvir
thiophen
analogu
lazerwith
et
al
bind
thumb
site
ii
hcv
polymeras
inhibit
viral
replic
gane
et
al
hcv
replicon
assay
ec
valu
less
nm
less
antivir
activ
rate
fenaux
et
al
phase
studi
combin
plu
ledipasvir
sofosbuvir
week
reach
rate
treatment
gtinfect
patient
cirrhosi
lawitz
et
al
anoth
phase
trial
patient
without
cirrhosi
maintain
treat
plu
ledipasvir
sofosbuvir
week
kohli
et
al
phase
trial
enrol
patient
without
cirrhosi
fourweek
treatment
danoprevir
ledipasvir
plu
sofosbuvir
rate
kohli
et
al
whether
would
enter
phase
clinic
trial
remain
unclear
thiophen
carboxyl
alloster
inhibitor
similar
improv
lomibuvir
led
discoveri
novel
thiophen
carboxyl
alloster
inhibitor
call
compound
court
et
al
fig
compound
improv
potenc
physicochem
properti
vitro
court
et
al
hcv
replicon
ec
valu
compound
reach
nm
nm
respect
court
et
al
compound
remain
preclin
phase
mericitabin
mericitabin
prodrug
cytidin
nucleosid
analogu
inhibit
hcv
polymeras
previous
mericitabin
consid
combin
danoprevir
infect
gane
et
al
pegifna
plu
ribavirin
infect
wedemey
et
al
former
therapi
exhibit
sever
advers
event
trial
gane
et
al
latter
therapi
rate
jumpc
trial
propel
trial
moreov
substitut
confer
lowlevel
resist
mericitabin
crossresist
sofosbuvir
roch
discontinu
mericitabin
due
decreas
number
particip
clinic
trial
deleobuvir
base
initi
hit
highthroughput
screen
compound
librari
nonnucleosid
inhibitor
deleobuvir
bi
optim
use
nmrguid
conform
restrict
scaffold
replac
laplant
et
al
healthi
patient
deleobuvir
welltoler
exhibit
moder
high
clearanc
favor
pharmacokinet
profil
chen
et
al
deleobuvir
discontinu
novel
inhibitor
dapn
phosphoramid
prodrug
metabol
intracellularli
two
distinct
bioactiv
nucleosid
triphosph
tp
analogu
effect
inhibit
rna
polymer
ehteshami
et
al
compound
present
novel
strategi
combin
intracellular
deliveri
two
inhibitori
metabolit
differ
incorpor
profil
nonzwitterion
macrocycl
exhibit
potent
antivir
activ
respect
crossgenotyp
coverag
viru
suppress
resist
select
nonnucleosid
inhibitor
combin
evalu
phase
clinic
trial
yet
resist
mutat
remain
concern
inform
phase
trial
avail
clinicaltrialsgov
filibuvir
nonnucleosid
inhibitor
filibuvir
bind
thumb
ii
alloster
pocket
prevent
hcv
subgenom
replicon
yi
et
al
ec
valu
filibuvir
achiev
nm
nm
respect
yi
et
al
moreov
substitut
could
affect
antivir
activ
filibuvir
yi
et
al
phase
studi
filibuvir
plu
pegifnarbv
welltoler
induc
signific
rna
reduct
patient
infect
wagner
et
al
phase
clinic
studi
acid
deriv
show
effect
potenc
signific
reduct
hcv
rna
patient
jiang
et
al
develop
filibuvir
discontinu
phase
trial
yet
unavail
clinicaltrialsgov
cnucleosid
class
inhibitor
de
clercq
discov
seri
optim
ecmethyl
adenosin
analogu
cnucleosid
monophosph
prodrug
exhibit
potent
activ
infect
ec
valu
mm
moreov
show
high
barrier
drug
resist
vitro
octob
absent
drug
pipelin
gilead
scienc
tegobuvir
tegobuvir
imidazopyridin
deriv
bind
bhairpin
palm
site
hcv
eltahla
et
al
shih
et
al
ec
valu
tegobuvir
less
nm
nm
phase
studi
show
confer
drug
resist
tegobuvir
patient
receiv
monotherapi
altogeth
clinic
use
tegobuvir
limit
advanc
daa
offer
pangenotyp
activ
better
efficaci
tegobuvir
discontinu
inhibitor
cyclic
phosphat
ester
deriv
class
uridin
nucleotid
prodrug
joncker
et
al
compound
profoundli
decreas
hcv
rna
level
mous
model
hcv
infect
dosedepend
manner
joncker
et
al
phase
trial
termin
clinicaltrialsgov
identifi
deriv
novel
deriv
quinolon
deriv
bind
alloster
site
exhibit
potent
antivir
activ
hcv
polymeras
ec
mm
ic
mm
manfroni
et
al
deriv
remain
preclin
stage
pyrazolobenzothiazin
novel
pyrazolobenzothiazin
discov
target
palm
site
exhibit
potent
antivir
effect
without
antimetabol
effect
hcv
replicon
assay
manfroni
et
al
drug
class
remain
preclin
stage
novemb
inhibitor
approv
fda
number
molecul
eg
lficolin
hame
et
al
neutral
viral
glycoprotein
lead
inhibit
viral
attach
hcv
viral
entri
although
inhibitor
remain
preclin
studi
hcv
entri
inhibitor
interest
offer
altern
strategi
clear
hcv
infect
qian
et
al
herein
highlight
newli
discov
compound
target
hcv
protein
fig
benzimidazol
deriv
primari
hepatocyt
novel
benzimidazol
deriv
inhibit
hcv
infect
dosedepend
pangenotyp
manner
vausselin
et
al
ic
valu
approxim
mm
mm
hcv
replicon
benzimidazol
deriv
may
interfer
hcv
entri
resist
profil
attribut
singl
mutat
hcv
vausselin
et
al
cynaropicringrosheimol
natur
product
cynaropicrin
grosheimol
extract
wild
egyptian
artichok
elsebai
et
al
two
compound
group
sesquiterpen
lacton
effici
inhibit
infect
elsebai
et
al
although
mechan
action
remain
unclear
cynaropicrin
grosheimol
may
interfer
hcv
viral
entri
elsebai
et
al
saikosaponin
saikosaponin
natur
occur
terpenoid
extract
bupleurum
kaoi
root
act
hcv
glycoprotein
lead
inhibit
hcv
infect
earli
stage
natur
product
show
pangenotyp
activ
act
noncytotox
concentr
clinic
use
saikosaponin
requir
investig
chlorcyclizin
deriv
chlorcyclizin
deriv
call
compound
optim
antihistamin
piperazin
drug
call
chlorcyclizin
hci
use
structureact
analysi
compound
may
act
interrupt
viral
entri
host
cell
compound
increas
antihcv
activ
select
hcv
replicon
assay
flunarizin
flunarizin
identifi
submicromolar
hcv
inhibitor
whole
life
cycl
screen
compound
librari
includ
clinic
approv
drug
perin
et
al
compound
target
fusion
peptid
inhibit
hcv
membran
fusion
genotypedepend
manner
perin
et
al
flunarizin
calcium
antagonist
effect
combat
pathophysiolog
migrain
antihcv
activ
prefer
genotyp
infect
prigozhin
modi
monoclon
antibodi
human
monoclon
antibodi
breadth
neutral
synergi
explor
inhibit
hcv
infect
carlsen
et
al
potent
neutral
antibodi
target
variou
epitop
hcv
envelop
protein
carlsen
et
al
adamantanerimantadin
structur
hcv
fulli
crystal
silico
compound
select
identifi
promis
agent
eg
adamantan
rimantadin
interf
base
highthroughput
screen
preliminari
analys
show
ration
develop
potent
drug
clinic
trial
still
requir
section
provid
overview
newli
discov
agent
inhibit
host
protein
eg
cyclophilin
cyclin
g
associ
kinas
scaveng
receptor
alisporivir
alisporivir
see
fig
nonimmunesuppress
compound
target
host
protein
cyclophilin
block
peptidylprolyl
cistran
isomeras
activ
pawlotski
et
al
addit
alisporivir
inhibit
interact
cyclophilin
dosedepend
manner
coelmont
et
al
interest
alisporivir
act
synergist
inhibitor
eg
daclatasvir
sofosbuvir
achiev
signific
antivir
effect
chatterji
et
al
moreov
alisporivir
stimul
antigen
present
promot
antigenspecif
cell
activ
therebi
lead
signific
antihcv
activ
essernobi
et
al
phase
studi
enrol
patient
rate
alisporivir
plu
pegifna
ribavirin
higher
alisporivir
alon
pawlotski
et
al
alisporivir
discontinu
phase
studi
due
sever
advers
event
unassoci
cyclophilin
inhibit
ahmedbelkacem
et
al
bisamid
deriv
pursu
cyclophilin
inhibitor
novel
bisamid
deriv
call
compound
discov
use
molecular
modelingbas
design
structureact
explor
compound
effici
inhibit
hcv
replic
restor
host
immun
respons
without
acut
toxic
vitro
vivo
fig
modifi
cyclosporin
analogu
act
nonimmunosuppress
cyclophilin
inhibitor
promis
pharmacokinet
profil
hcv
infect
fu
et
al
comparison
alisporivir
decreas
transport
inhibit
maintain
compar
efficaci
cyclophilin
fu
et
al
phenylepyrrolidin
deriv
phenylepyrrolidin
deriv
fig
discov
inhibit
cyclophilin
use
nucleic
magnet
reson
xray
crystallographi
structurebas
compound
optim
ahmedbelkacem
et
al
ec
valu
inhibitor
mm
cell
addit
inhibitor
could
broadspectrum
highbarriertoresist
inhibitor
hiv
coronavirus
well
ahmedbelkacem
et
al
isothiazolo
pyridin
isothiazolo
pyridin
develop
target
cyclin
g
associ
kinas
gak
serinethreonin
protein
kinas
associ
cyclin
g
cell
cycl
regul
kovackova
et
al
known
gak
essenti
hcv
entri
assembl
kovackova
et
al
drug
mechan
isothiazolo
pyridin
therebi
trace
inhibit
upon
hcv
entri
assembl
kovackova
et
al
lead
deriv
isothiazolo
pyridin
show
potent
antihcv
activ
k
nm
kovackova
et
al
fig
inhibitor
scaveng
receptor
essenti
receptor
hcv
entri
syder
et
al
host
factor
antagonist
could
combin
daa
without
confer
crossresist
vitro
phase
clinic
trial
mg
per
day
day
safe
well
toler
sulkowski
et
al
fig
lipocyclodepsipeptid
isol
ferment
broth
pseudomona
sp
shimura
et
al
effect
inhibit
hcv
entri
possibl
antivir
mechan
trace
interact
hcv
entri
receptor
call
use
phase
display
screen
surfac
plasmon
reson
bind
analys
shimura
et
al
soraphen
natur
product
soraphen
myxobacteri
metabolit
interfer
membran
web
format
lead
inhibit
hcv
replic
ec
valu
soraphen
nm
hcv
infect
review
provid
overview
fdaapprov
therapi
newli
discov
agent
hcv
infect
moreov
studi
present
first
detail
survey
drug
efficaci
fdaapprov
therapi
base
clinic
trial
realworld
studi
similar
hiv
cocktail
therapi
hcv
combin
therapi
contain
two
three
daa
block
differ
stage
viral
life
cycl
offer
favor
inhibitori
efficaci
low
incid
side
effect
unlik
first
gener
antihcv
drug
pegyl
interferon
ribavirin
mani
fdaapprov
daa
directli
bind
hcv
protein
furthermor
pursuit
next
gener
antihcv
inhibitor
yield
larg
number
investig
agent
novel
mechan
drug
action
inhibitor
synthes
inhibit
hcv
protein
human
protein
eg
cyclophilin
cyclin
g
associ
kinas
scaveng
receptor
accumul
past
five
year
larg
pool
fdaapprov
drug
promis
experiment
inhibitor
provid
strong
reinforc
cure
hcv
infect
patient
nevertheless
mani
challeng
lie
ahead
develop
next
gener
daa
hcv
infect
worldwid
popul
first
challeng
develop
effect
therapi
difficulttotreat
popul
hcvinfect
patient
endstag
renal
diseas
moral
fabrizi
hcvinfect
patient
kidney
transplant
ferenc
gambato
et
al
hcvinfect
patient
liver
graft
infect
felmle
et
al
hcvinfect
patient
compens
decompens
cirrhosi
suggest
treat
hcvinfect
patient
earli
diseas
cours
may
prevent
hcvrelat
cirrhosi
complic
aasldidsa
hcv
guidanc
panel
whilst
preemptiv
daa
treatment
may
benefit
prevent
treatment
liver
graft
infect
felmle
et
al
recent
studi
report
unexpect
high
rate
earli
tumor
recurr
treatment
daa
hcvinfect
patient
prior
hepatocellular
carcinoma
reig
et
al
despit
high
potenc
daa
occurr
liver
cancer
reduc
hcvinfect
cirrhot
patient
sustain
virolog
respons
nevertheless
follow
studi
integr
three
distinct
prospect
cohort
show
increas
risk
hcc
recurr
patient
daa
treatment
thecollabor
st
whether
daa
treatment
increas
hcc
occurr
recurr
rate
remain
subject
debat
larg
patient
cohort
emerg
proper
control
arm
assess
import
question
llovet
villanueva
second
challeng
demand
request
pangenotyp
drug
minim
drug
resist
one
hand
crucial
appli
pangenotyp
therapi
hcv
genotyp
especi
genotyp
test
unavail
resourcelimit
area
today
epclusa
therapi
approv
treatment
infect
hand
drug
resist
remain
concern
natur
variat
differ
genotyp
may
confer
resist
genotypespecif
drug
sarrazin
pawlotski
instanc
resistanceassoci
substitut
present
patient
prior
treatment
ledipasvir
plu
sofosbuvir
presenc
exert
neg
impact
treatment
outcom
moreov
hcv
variant
within
region
reduc
sensit
nucleotid
analogu
eg
sofosbuvir
also
increas
viral
fit
cell
cultur
system
ramirez
et
al
addit
mani
inhibitor
show
potent
activ
polymorph
hcv
genotyp
drug
bind
pocket
well
substanti
loss
intermolecular
hydrogen
bond
interact
dynam
crosscorrel
inhibitor
activ
site
soumana
et
al
list
hcv
resistanceassoci
substitut
avail
sarrazin
pawlotski
altogeth
develop
pangenotyp
drug
remain
import
third
challeng
optim
simpl
regimen
low
pill
burden
shorter
treatment
durat
recent
attempt
made
shorten
cours
antihcv
treatment
recommend
week
week
even
less
instanc
find
openlabel
phase
trial
suggest
week
responseguid
therapi
eg
sofosbuvir
ledipasvir
asunaprevir
sofosbuvir
daclatasvir
simeprevir
sofosbuvir
daclatasvir
asunaprevir
accomplish
rate
drastic
reduc
cost
therapi
improv
drug
adher
elimin
incid
advers
event
anoth
phase
studi
ledipasvir
plu
sofosbuvir
week
also
exhibit
patient
acut
monoinfect
deterd
et
al
novel
hcv
therapeut
may
aim
shorter
treatment
durat
optim
efficaci
given
breakthrough
achiev
current
daa
anticip
next
decad
wit
substanti
decreas
hcv
infect
global
popul
ultim
erad
hcv
infect
also
requir
univers
diagnosi
hcv
infect
improv
access
health
care
potenti
implement
prophylact
hcv
vaccin
supplement
review
updat
hcv
drug
develop
avail
onlin
platform
http
wwwvirusfacecom
